Highlights

  • Consensus rating of Buy from 7 analysts: 4 Buy or equivalent, 3 Hold, 0 Sell or equivalent.
  • Mean price target of A$18.45 against a share price of A$7.93 on 8 October 2026, an implied upside of 132.7%.
  • Analyst targets range from A$9.52 to A$39.30.
  • A Dividend of $0.05 per ordinary share was declared.

Clinuvel (ASX:CUV) carries a consensus analyst rating of Buy. Of the 7 analyst recommendations recorded, 4 are Buy or equivalent, 3 are Hold and 0 are Sell or equivalent. The mean price target is A$18.45, with targets ranging from A$9.52 to A$39.30, against a current share price of A$7.93 (8 October 2026). Clinuvel Pharmaceuticals Limited is a biopharmaceutical company listed on the ASX and Nasdaq that develops and commercialises treatments including SCENESSE.

Company name

Clinuvel

Ticker

(ASX:CUV)

Exchange

ASX (Australian Securities Exchange)

Current share price

A$7.93

Price date

8 October 2026

Number of analysts

7

Rating consensus

Buy

Consensus price target (mean)

A$18.45

Highest target

A$39.30

Lowest target

A$9.52

Implied upside/downside to mean target

Implied upside of 132.7%

Latest developments

Clinuvel Pharmaceuticals (ASX:CUV; Nasdaq:CUVL) announced on 27 August 2026 its tenth consecutive annual profit and a further rise in free cash for the year ended 30 June 2026. A dividend of $0.05 per ordinary share was declared. Revenues were $94.0 million, down 1%, and revenues plus interest and other income were $101.2 million, down 4%. Expenses were $53.5 million, down 0.5%.

Net profit before income tax was $47.7 million, down 8%, and net profit after income tax was $33.9 million, down 6%. Basic Earnings Per Share were $0.68, compared with $0.72. Cash reserves were $252.1 million, up 12%, and net tangible assets backing per share were $5.35, compared with $4.77. The company said its cash position provides flexibility for its U.S. expansion strategy.

Sector context

Specialty pharmaceutical results depend on product sales, regulatory approvals and clinical programs. The company is building its operations and Capital Markets presence in the United States.

Risks and what to watch

Revenue, profit before tax and net profit all declined, with net profit after tax down 6%. The company is investing in a U.S. expansion, which adds costs and execution requirements. Targets in the consensus data are widely spread, from A$9.52 to A$39.30, and Revenue depends on a limited product range.

Next milestones

Items to watch include payment of the $0.05 dividend, progress of the U.S. expansion, product sales and regulatory developments, and the company's half-year result.